Skip to main content
OpenTrials
Completed

NCT Number: NCT03028025

Comparing TR Band to Statseal in Conjunction With TR Band

The primary objectives of this study are to evaluate the performance of StatSeal Advanced used in conjunction with the TR Band (SSA) as compared to the TR Band without SSA (TRB) relative to: the incidence of peri-procedural radial artery occlusion (RAO) at discharge or 24 hours, whichever occurs first, and the Time to Hemostasis (TTH).

Completed

Looking for future studies?

Notify Me

Key information

About this study

This study is a physician initiated, prospective, observational, two arm, randomized study to be performed at up to four experienced 'Radial First' centers (UCSD, UCLA. Arkansas Heart Hospital and LBVA). A maximum of 180 patients having undergone successful radial catheterization will be enrolled in the study, 60 in each arm. 60 patients will be enrolled at the LBVA. Enrollment will continue at each site on discretion of the investigators until each center enrolls a minimum of 30 patients, or a maximum of 180 patients are enrolled. Clinicians will perform the catheterization in accordance with local standard practice, with a minimum of 5,000 units of unfractionated heparin for anticoagulation. At the start of the TRA procedure, prior to radial artery cannulation, a baseline Pleth-ox exam will be performed for all patients and recorded on the CRF. Ulnar compression will be applied to confirm that the radial artery is patent. Patients with a type D pattern exam will be excluded from the study. At the conclusion of a successful transradial procedure, the patient will be randomized to either SSA or TRB, each device applied per protocol & IFU. It is hypothesized that if radial artery compression time can be shortened to 40 minutes or less, the following could result: improved catheterization lab efficiency, greater patient satisfaction and lower complication rates, including RAO, may be improved.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient undergoing diagnostic angiography or PCI via the radial artery
  • Patients with a Barbeau test prior to the procedure showing pattern A,B,or

Exclusion criteria

  • Use of a radial sheath larger than 6 Fr (a 7Fr-in-6 Glidesheath Slender ® is allowed).
  • Use of an anticoagulant other than unfractionated heparin or bivalirudin.
  • Any anticipated need for continued anticoagulation post-catheterization. Glycoprotein inhibitors are acceptable.
  • Any active treatment with oral anticoagulants continued during course of procedure.
  • Presence of arteriovenous dialysis fistula in the ipsilateral arm.
  • Any physical deformity or trauma / injury of either wrist that would prevent proper placement or function of the hemostasis band.
  • Raynaud's syndrome or known peripheral vascular disease of the forearm.
  • Mental incompetence or inability to follow the instructions to complete the study.
  • History or presence of Radial Artery Occlusion.
  • Barbeau test showing Pattern D.
  • Patients undergoing catheterization from the femoral or ulnar artery approach.
  • Cardiogenic shock or any clinical instability as assessed by the physician performing the procedure.

Treatment and study plan

Statseal

Device

Patients randomly assigned to the experimental group will have a Statseal Advance (SSA) disc applied after withdrawing the radial sheath 2-4 cm. A Tegaderm dressing will be applied to secure the disc position. The TR band will be applied over the SSA disc with the center of the balloon (the green dot) over the center of the SSA disc. The TR band will be inflated with 8cc of air (which is typically occlusive pressure), and the sheath removed. No deflation will occur immediately. After 20 minutes of pressure, 3 cc of air will be removed from the TR band. After an additional 20 minutes (40 minutes after procedure), the TR band will be completely deflated, and the TR band left in place. After an additional 20 minutes (60 minutes after procedure) the TR band will be removed.

Other names: potassium ferrate disc with topical hydrophilic polymer

TR Band

Device

Patients randomly assigned to the control group will have a TR band applied over the arteriotomy site and inflated with 15-18ml of air. After aspirating and clearing the contents of the sheath, the radial sheath will be removed. The TR band will be deflated until bleeding occurs, and 2 ml of air will be reintroduced to provide hemostasis. Patent hemostasis will be documented with plethysmography and oximetry as described below within 5 minutes after band application and removal, and within 30 min of discharge or after 24 hours. The TR band will be left inflated and in place for 2 hours following the procedure for all patients (regardless of diagnostic or PCI procedure), after which deflation attempts will commence.

Other names: Hemostasis device

Primary outcomes

  1. Time to Hemostasis Using the Hemostasis Management System (HMS)

    Time frame: within 30 min of discharge or after 24 hours

    Time to deflation for removal of the TR Band (or TR Band and Statseal) for each group was measured in minutes.

Secondary outcomes

  1. Percent of Patients With Radial Artery Occlusion(RAO)

    Time frame: within 30 min of discharge or after 24 hours

    Radial artery occlusion was monitored for all participants using Barbeau's test and pulse oximetry.

Sponsors and collaborators

Lead sponsor

VA Long Beach Healthcare System

Fed

Registry information

Official study title

Radial Hemostasis is Facilitated With a Potassium Ferrate Hemostatic Patch (Statseal): the Randomized Controlled Statseal With TR Band Assessment Trial (STAT)

Important dates

Study start
2017
Primary completion
2017
Study completion
2017
First posted
Jan 23, 2017
Registry last updated
Apr 21, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.